LipidRescue is under clinical development by ResQ Pharma and currently in Pre-Registration for Drug Toxicity. According to GlobalData, Pre-Registration drugs for Drug Toxicity have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how LipidRescue’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LipidRescue overview
Lipid rescue therapy (LRT) is under development for the treatment of local anesthetic systemic toxicity (LAST) and for the toxicity, overdose of non-opioid drugs (NODO), ischemic reperfusion injury (IRI). LRT contains lipid emulsions administered as an intravenous infusion.
ResQ Pharma overview
ResQ Pharma is a research and development company. The company is headquartered in Chicago, Illinois, the US
For a complete picture of LipidRescue’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.